Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: Insights on safety, target validation, and mechanism of action

International Journal for Parasitology

Volumn 29, Issue 6, 1999, Pages 833-837

  McKerrow, James H ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cysteine; Inhibitor; Metabolism; Parasite; Protease; Safety

Indexed keywords

CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; CONFERENCE PAPER; DOG; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; HELMINTHIASIS; LEISHMANIA; MOUSE; NONHUMAN; PARASITOSIS; PLASMODIUM FALCIPARUM; PROTOZOAL INFECTION; RAT; SCHISTOSOMA; TOXOPLASMA; TRYPANOSOMA CRUZI;

ANIMALS; ANTIPARASITIC AGENTS; ANTIPROTOZOAL AGENTS; CYSTEINE PROTEINASE INHIBITORS; HELMINTHIASIS; HELMINTHS; HUMANS; PARASITIC DISEASES; PROTOZOA; PROTOZOAN INFECTIONS; SCHISTOSOMICIDES;

ANIMALIA; PLASMODIUM FALCIPARUM; PROTOZOA; TRYPANOSOMA; TRYPANOSOMA CRUZI; VERMES;

EID: 0032781317     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7519(99)00044-2     Document Type: Conference Paper

References (24)

1. McKerrow J.H., Sun E., Rosenthal P.J., Bouvier J. The proteases and pathogenicity of parasitic protozoa. Ann Rev Microbiol. 47:1993;821-853.
2. Mottram J.C., Souza A.E., Hutchison J.E., Carter R., Frame M.J., Coombs G.H. Evidence from disruption of the lmcpb gene array of Leishmania mexicana that cysteine proteinases are virulence factors. Proc Nat Acad Sci, USA. 93:1996;6008-6013.
3. Robertson C.D., North M.J., Lockwood B.C., Coombs G.H. Analysis of the proteinases of Trypanosoma brucei. J Gen Microbiol. 136:1990;921-925.
4. McKerrow JH, Engel JC, Caffrey CR. Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorganic Med Chem, in press.
5. Moyle G.J., Youle M., Higgs C.et al. Safety, pharmacokinetics, and antiretrovial activity of the potent, specific human immonodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J Clin Pharmacol. 38:1998;736-743.
6. Hodgson J. Remodeling MMPIs. Bio/Technology. 13:1995;554-557.
7. Rosenthal P.J., Lee G.K., Smith R.E. Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. J Clin Invest. 91:1993;1052-1056.
8. Engel J.C., Doyle P.S., Hsieh I., McKerrow J.H. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med. 188:1998;725-734.
9. Engel J.C., Doyle P.S., Palmer J., Hsieh I., Bainton D.F., McKerrow J.H. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J Cell Sci. 111:1998;597-606.
10. Rasnick D. Small synthetic inhibitors of cysteine proteases. In: McKerrow JH, James MNG, editors. Cysteine proteases. 6. Leiden: ESCOM, 1996:47-63.
11. Amos HE, Park BK. In: Dean JH, Luster MI, Munson AE, Amos HE, editors. Immunotoxicology and immunopharmacology. New York: Raven, 1985:207-228.
12. SRI International Report #M001-98, #1382-408, 1998.
13. McKerrow J.H., James M.N.G. Cysteine proteases. Perspectives in drug discovery and design. ESCOM. 6:1996;125.
14. Bond J.S., Butler P.E. Intracellular proteases. Ann Rev Biochem. 56:1987;333-364.
15. Mason RW. Proteinases of mammals: an overview. In: Coombs GH, North MJ, editors. Biochemical protozoology. London, New York, Philadelphia: Taylor and Francis, 1991:168-179.
16. McGrath M.E., Eakin A.E., Engel J.C., McKerrow J.H., Craik C.S., Fletterick R.J. The crystal structure of cruzain: a therapeutic target for Chagas' disease. J Mol Biol. 247:1995;251-259.
17. Bogyo M., McMaster J.S., Gaczynska M., Tortorella D., Goldberg A.L., Ploegh H. Covalent modification of the active site threonine of proteasomal β subunits and the Escherichia coli homolog HsIV by a new class of inhibitors. Proc Nat Acad Sci, USA. 94:1997;6629-6634.
18. Serveau C., Lalmanach G., Juliano M.A., Scharfstein J., Juliano L., Gauthier F. Investigation of the substrate specificity of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, through the use of cystatin-derived substrates and inhibitors. J Biochem. 313:1996;951-956.
19. Lalmanach G., Mayer R., Serveau C., Scharfstein J., Gauthier F. Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanasoma cruzi. J Biochem. 318:1996;395-399.
20. Zhang Y., Guo X., Lin E.T., Benet L.Z. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. Drug Metab Disp. 26:1998;360-366.
21. Rosenthal PJ, McKerrow JH, Rasnick D, Leech JH. A cysteine proteinase of Plasmodium falciparum is a potential target of antimalarial chemotherapy. Bioorganic Med Chem, in press.
22. Troeberg L., Pike R.N., Morty R.E., Berry R.K., Coetzer T.H.T., Lonsdale-Eccles J.D. Proteases from Trypanosoma brucei brucei. Purification, characterisation and interactions with host regulatory molecules. Eur J Biochem. 238:1996;728-736.
23. Selzer P.M., Chen X., Chan V.J.et al. Leishmania major: molecular modeling of cysteine proteases and prediction of new nonpeptide inhibitors. Exp Parasitol. 87:1997;212-221.
24. Wasilewski M.M., Lim K.C., Phillips J., McKerrow J.H. Cysteine protease inhibitors block schistosome hemoglobin degradation in vitro and decrease worm burden and egg production in vivo. Mol Biochem Parasitol. 61:1996;179-189.